drugset
drugset / Trial / NCT04335253

First-In-Human Study of EOS884448 in Participants with Advanced Cancers.

NCT04335253 ↗

Phase 1 Completed 40 enrolled iTeos Therapeutics iTeos Belgium SA · collab
NaSequentialOpen-labelTreatment

Summary

IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.

Timeline

Start
2020-02-18
Primary completion
2022-04-07
Completion
2022-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Belrestotug Monoclonal antibody — —

Indications

cancer of unknown primary site